Table 1.
Clinical characteristics at baseline.
| Characteristics | n = 34 |
|---|---|
| Median age, years (range) | 60.5 (39–73) |
| M/F | 18/16 |
| ECOG Performance status | |
| 0 | 18 (53%) |
| 1 | 13 (38.2%) |
| 2 | 3 (8.8%) |
| M-protein type | |
| IgG | 20 (58.8%) |
| Light chain | 5 (14.7%) |
| IgD | 1 (2.9%) |
| IgA | 7 (20.6%) |
| Not specified | 1 (2.9%) |
| Type of free light chains | |
| κ/λ | 17 (50%)/17 (50%) |
| R-ISS stage | |
| 1 | 14 (41.2%) |
| 2 | 12 (35.3%) |
| 3 | 8 (23.5%) |
| Cytogenetic abnormalities | |
| del(17p) | 4 (11.8%) |
| Normal | 15 (44.1%) |
| Others | 6 (17.6%) |
| Not performed | 9 (26.5%) |
| Median BM plasma cells, % (range) | 46 (10–80) |
| Median M-protein, g/dL (range) | 2.68 (0–5.9) |
| Median involved chain, mg/L (range) | 128 (7.9–19,300) |
| Median uninvolved chain, mg/L (range) | 9.1 (1.8–54.6) |
| Median FLC ratio | 16.15 (1–3641) |
| Increased FLC ratio | 28/34 (82%) |
| Presence of urinary Bence Jones protein | 20/34 (58.8%) |
| Median β2-microglobulin, mg/dL (range) | 3.3 (1.4–19) |
| Median LDH, U/L (range) | 395 (217–901) |
| Median albumin, g/dL (range) | 3.35 (2–4.9) |
Abbreviations. Ig, immunoglobulin; R-ISS, revised international staging system; BM, bone marrow; FLC, free light chain; LDH, lactate dehydrogenase.